Literature DB >> 21674705

Apoptosis resistance of mucosal lymphocytes and IL-10 deficiency in patients with steroid-refractory Crohn's disease.

Rebeca Santaolalla1, Josep Mañé, Elisabet Pedrosa, Violeta Lorén, Fernando Fernández-Bañares, Josefa Mallolas, Anna Carrasco, Antonio Salas, Mercè Rosinach, Montserrat Forné, Jorge C Espinós, Carme Loras, Michael Donovan, Pere Puig, Miriam Mañosa, Miquel A Gassull, Josep M Viver, Maria Esteve.   

Abstract

BACKGROUND: Apoptosis resistance of T-cells is considered an abnormality of immune pathways in Crohn's disease (CD). It has been previously shown that corticosteroids induce apoptosis of cells involved in inflammation. Thus, our aim was to assess the apoptosis of mononuclear cells and pro/antiinflammatory cytokines in the intestinal mucosa of patients with active CD, related to steroid response, and identify cellular and molecular factors that may predict this response to therapy.
METHODS: Patients with CD (n = 26), ulcerative colitis (UC) (n = 32), and controls (n = 10) were prospectively studied with mucosal biopsies before and 7-10 days after corticosteroid treatment. Immunophenotype and apoptosis of T and B lymphocytes, plasma cells, and macrophages were assessed by flow cytometry, immunohistochemistry, and immunofluorescence. The cytokine expression pattern was evaluated by quantitative polymerase chain reaction (PCR).
RESULTS: Apoptosis resistance of T and B lymphocytes was observed only in steroid-refractory and -dependent CD patients as compared to responsive patients (P = 0.032; P = 0.004, respectively), being evident after steroid treatment. Interleukin (IL)-10 was markedly increased at baseline in steroid-responsive patients compared to the nonresponders (P = 0.006; sensitivity: 88.8%; specificity: 66.6% to predict steroid response).
CONCLUSIONS: Apoptosis resistance of mucosal T and B cells in steroid-refractory and -dependent CD patients appears during the evolution of the acute phase, limiting its clinical application as a predictor marker. In contrast, increased expression of IL-10 at an early stage of active steroid-sensitive CD patients supports its usefulness at predicting a good steroid response. Steroid-dependent and -refractory CD patients share similar molecular and cellular pathophysiological mechanisms.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21674705     DOI: 10.1002/ibd.21507

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  12 in total

Review 1.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Apple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression.

Authors:  Jerod A Skyberg; Amy Robison; Sarah Golden; Maryclare F Rollins; Gayle Callis; Eduardo Huarte; Irina Kochetkova; Mark A Jutila; David W Pascual
Journal:  J Leukoc Biol       Date:  2011-06-21       Impact factor: 4.962

3.  Role of the advanced glycation end products receptor in Crohn's disease inflammation.

Authors:  Rachele Ciccocioppo; Alessandro Vanoli; Catherine Klersy; Venerina Imbesi; Vincenzo Boccaccio; Rachele Manca; Elena Betti; Giuseppina Cristina Cangemi; Elena Strada; Roberta Besio; Antonio Rossi; Colomba Falcone; Sandro Ardizzone; Paolo Fociani; Piergiorgio Danelli; Gino Roberto Corazza
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 4.  Why interleukin-10 supplementation does not work in Crohn's disease patients.

Authors:  Gareth J Marlow; Dominique van Gent; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

5.  Interleukin-10 Enhances the Intestinal Epithelial Barrier in the Presence of Corticosteroids through p38 MAPK Activity in Caco-2 Monolayers: A Possible Mechanism for Steroid Responsiveness in Ulcerative Colitis.

Authors:  Violeta Lorén; Eduard Cabré; Isabel Ojanguren; Eugeni Domènech; Elisabet Pedrosa; Arce García-Jaraquemada; Miriam Mañosa; Josep Manyé
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

6.  Recombinant adeno-associated virus carrying thymosin β4 suppresses experimental colitis in mice.

Authors:  Xiao-Yan Zheng; Yi-Fei Lv; Shuang Li; Qian Li; Qian-Nan Zhang; Xue-Ting Zhang; Zhi-Ming Hao
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

Review 7.  Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.

Authors:  Karen Dubois-Camacho; Payton A Ottum; Daniel Franco-Muñoz; Marjorie De la Fuente; Alejandro Torres-Riquelme; David Díaz-Jiménez; Mauricio Olivares-Morales; Gonzalo Astudillo; Rodrigo Quera; Marcela A Hermoso
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

8.  Early induction of C/EBPβ expression as a potential marker of steroid responsive colitis.

Authors:  Mushref Bakri Assas; Scott Levison; Joanne L Pennock
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

9.  Defective apoptosis in intestinal and mesenteric adipose tissue of Crohn's disease patients.

Authors:  Cilene Bicca Dias; Marciane Milanski; Mariana Portovedo; Vivian Horita; Maria de Lourdes Setsuko Ayrizono; Núria Planell; Cláudio Saddy Rodrigues Coy; Lício Augusto Velloso; Luciana Rodrigues Meirelles; Raquel Franco Leal
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

Review 10.  Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease.

Authors:  Paolo Giuffrida; Sara Cococcia; Mariangela Delliponti; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Cells       Date:  2019-04-30       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.